The general aim of this study was to evaluate the neurophysiological changes of wet AMD patients after the anti-VEGF treatment and to assess whether whole-field pattern VEP could be used as a monitoring tool of AMD patients. In addition, the cost-effectiveness of AMD treatment was evaluated.
The specific aims were as follows:
I To identify the possible visual evoked potential changes after the anti-VEGF treatment (Publication I).
II To evaluate if visual evoked potential changes correlate with clinical findings of treated patients (Publication II).
III To study whether binocular face detection is affected by monocular wet AMD (Publication III).
IV To construct a two-eye Markov transition model for the cost-effective analysis of AMD treatment and to identify the most cost-effective treatment protocol and medication for wet AMD (Publication IV).
65
9 Conclusions
I In wet AMD VEP is abnormal. The anti-VEGF treatment of wet AMD patients exerts an effect on the neurophysiological responses. VEP amplitudes appear to increase after treatment, suggesting that there is improved visual processing.
II In treated wet AMD patients, the improvement in visual acuity and the increase in VEP amplitude are associated with a decrease in retinal thickness as measured by OCT.
However, there is no evidence from short term follow-up that VEP confers added value in the diagnosis or monitoring of wet AMD.
III Monocular wet AMD clearly influenced face-specific brain electrophysiological components. However, our wet AMD patients had not lost their binocular face detection ability. This supports the view that only the vision of the better seeing eye has a marked influence on every-day life.
IV In the cost-effectiveness analysis of wet AMD treatment, monthly injected bevacizumab is the most cost effective treatment and; monthly treatment with ranibizumab being the least cost effective.
66
67
10 References
ABRAHAM, P., YUE, H. and WILSON, L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology, 2010;150(3):315-324.e1.
ACHEN, M.G., JELTSCH, M., KUKK, E., MAKINEN, T., VITALI, A., WILKS, A.F., ALITALO, K. and STACKER, S.A., Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proceedings of the National Academy of Sciences of the United States of America, 1998;95(2):548-553.
ADATIA, F.A., LUONG, M., MUNRO, M. and TUFAIL, A., The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents. Survey of ophthalmology, 2015;60(3):204-215.
AGE-RELATED EYE DISEASE STUDY 2 RESEARCH GROUP, Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. Jama, 2013;309(19):2005-2015.
AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of ophthalmology (Chicago, Ill.: 1960), 2001;119(10):1417-1436.
AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP, Risk factors associated with age-related macular degeneration. A case-control study in the age-age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology, 2000;107(12):2224-2232.
AMADIO, M., GOVONI, S. and PASCALE, A., Targeting VEGF in eye neovascularization:
What's new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacological research, 2016;103:253-269.
AMOAKU, W.M., CHAKRAVARTHY, U., GALE, R., GAVIN, M., GHANCHI, F., GIBSON, J., HARDING, S., JOHNSTON, R.L., KELLY, S.P., LOTERY, A., MAHMOOD, S., MENON, G., SIVAPRASAD, S., TALKS, J., TUFAIL, A. and YANG, Y., Defining response to anti-VEGF therapies in neovascular AMD. Eye (London, England), 2015;29(6):721-731.
ANASTASOPOULOS, E., YU, F. and COLEMAN, A.L., Age-related macular degeneration is associated with an increased risk of hip fractures in the Medicare database. American Journal of Ophthalmology, 2006;142(6):1081-1083.
ARIAS, L., CAMINAL, J.M., CASAS, L., MASUET, C., BADIA, M.B., RUBIO, M., PUJOL, O. and ARRUGA, J., A study comparing two protocols of treatment with intravitreal bevacizumab
68
(Avastin) for neovascular age-related macular degeneration. The British journal of ophthalmology, 2008;92(12):1636-1641.
ARNOLD, J.J. and HERIOT, W., Age related macular degeneration. BMJ clinical evidence, 2007:0701.
ATHANASAKIS, K., FRAGOULAKIS, V., TSIANTOU, V., MASAOUTIS, P., MANIADAKIS, N.
and KYRIOPOULOS, J., Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Clinical therapeutics, 2012;34(2):446-456.
BAJWA, A., AMAN, R. and REDDY, A.K., A comprehensive review of diagnostic imaging technologies to evaluate the retina and the optic disk. International ophthalmology, 2015;35(5):733-755.
BAKER, C.I., DILKS, D.D., PELI, E. and KANWISHER, N., Reorganization of visual processing in macular degeneration: replication and clues about the role of foveal loss. Vision research, 2008;48(18):1910-1919.
BARNES, C.S., DE L'AUNE, W. and SCHUCHARD, R.A., A test of face discrimination ability in aging and vision loss. Optometry and vision science: official publication of the American Academy of Optometry, 2011;88(2):188-199.
BASELER, H.A., GOUWS, A., CROSSLAND, M.D., LEUNG, C., TUFAIL, A., RUBIN, G.S. and MORLAND, A.B., Objective visual assessment of antiangiogenic treatment for wet age-related macular degeneration. Optometry and vision science: official publication of the American Academy of Optometry, 2011a;88(10):1255-1261.
BASELER, H.A., GOUWS, A., HAAK, K.V., RACEY, C., CROSSLAND, M.D., TUFAIL, A., RUBIN, G.S., CORNELISSEN, F.W. and MORLAND, A.B., Large-scale remapping of visual cortex is absent in adult humans with macular degeneration. Nature neuroscience, 2011b;14(5):649-655.
BASS, S.J., SHERMAN, J., BODIS-WOLLNER, I. and NATH, S., Visual evoked potentials in macular disease. Investigative ophthalmology & visual science, 1985;26(8):1071-1074.
BECK, M., MUNK, M.R., EBNETER, A., WOLF, S. and ZINKERNAGEL, M.S., Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2016;167:10-17.
BEGG, D., FISCHER, S. and DORNBUSCH, R., Economics and the Economy. Economics.
Bergshire, England. McGraw-Hill Book Company Europe. 1997;2-13.
69
BEGLEITER, H., PORJESZ, B. and WANG, W., Event-related brain potentials differentiate priming and recognition to familiar and unfamiliar faces. Electroencephalography and clinical neurophysiology, 1995;94(1):41-49.
BELLMANN, C., FEELY, M., CROSSLAND, M.D., KABANAROU, S.A. and RUBIN, G.S., Fixation stability using central and pericentral fixation targets in patients with age-related macular degeneration. Ophthalmology, 2004;111(12):2265-2270.
BENTIN, S., GOLLAND, Y., FLEVARIS, A., ROBERTSON, L.C. and MOSCOVITCH, M., Processing the trees and the forest during initial stages of face perception: electrophysiological evidence. Journal of cognitive neuroscience, 2006;18(8):1406-1421.
BINDEMANN, M., BURTON, A.M., LEUTHOLD, H. and SCHWEINBERGER, S.R., Brain potential correlates of face recognition: geometric distortions and the N250r brain response to stimulus repetitions. Psychophysiology, 2008;45(4):535-544.
BIRD, A.C., BRESSLER, N.M., BRESSLER, S.B., CHISHOLM, I.H., COSCAS, G., DAVIS, M.D., DE JONG, P.T., KLAVER, C.C., KLEIN, B.E. and KLEIN, R., An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Survey of ophthalmology, 1995;39(5):367-374.
BLOCH, S.B., LARSEN, M. and MUNCH, I.C., Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. American Journal of Ophthalmology, 2012;153(2):209-213.e2.
BOURNE, R.R., STEVENS, G.A., WHITE, R.A., SMITH, J.L., FLAXMAN, S.R., PRICE, H., JONAS, J.B., KEEFFE, J., LEASHER, J., NAIDOO, K., PESUDOVS, K., RESNIKOFF, S., TAYLOR, H.R. and VISION LOSS EXPERT GROUP, Causes of vision loss worldwide, 1990-2010: a systematic analysis. The Lancet. Global health, 2013;1(6):e339-49.
BRAR, V.S., SHARMA, R.K., MURTHY, R.K. and CHALAM, K.V., Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Molecular vision, 2010;16:1848-1853.
BRESSLER, N.M., CHANG, T.S., SUNER, I.J., FINE, J.T., DOLAN, C.M., WARD, J., IANCHULEV, T. and MARINA AND ANCHOR RESEARCH GROUPS, Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology, 2010;117(4):747-56.e4.
BRIGGS, A. and SCULPHER, M., An introduction to Markov modelling for economic evaluation. PharmacoEconomics, 1998;13(4):397-409.
BRIGGS, A.H. and GRAY, A.M., Handling uncertainty when performing economic evaluation of healthcare interventions. Health technology assessment (Winchester, England), 1999;3(2):1-134.
70
BRODY, B.L., GAMST, A.C., WILLIAMS, R.A., SMITH, A.R., LAU, P.W., DOLNAK, D., RAPAPORT, M.H., KAPLAN, R.M. and BROWN, S.I., Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology, 2001;108(10):1893-900; discussion 1900-1.
BROWN, D.M., KAISER, P.K., MICHELS, M., SOUBRANE, G., HEIER, J.S., KIM, R.Y., SY, J.P., SCHNEIDER, S. and ANCHOR STUDY GROUP, Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The New England journal of medicine, 2006;355(14):1432-1444.
BROWN, G.C., Vision and quality-of-life. Transactions of the American Ophthalmological Society, 1999;97:473-511.
BROWN, G.C., SHARMA, S., BROWN, M.M. and KISTLER, J., Utility values and age-related macular degeneration. Archives of Ophthalmology, 2000;118(1):47-51.
BUCH, H., NIELSEN, N.V., VINDING, T., JENSEN, G.B., PRAUSE, J.U. and LA COUR, M., 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology, 2005;112(5):787-798.
BULLIMORE, M.A., BAILEY, I.L. and WACKER, R.T., Face recognition in age-related maculopathy. Investigative ophthalmology & visual science, 1991;32(7):2020-2029.
BURNAT, K., Are visual peripheries forever young? Neural plasticity, 2015;2015:307929.
BUSBEE, B.G., HO, A.C., BROWN, D.M., HEIER, J.S., SUNER, I.J., LI, Z., RUBIO, R.G., LAI, P.
and HARBOR STUDY GROUP, Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ophthalmology, 2013;120(5):1046-1056.
BUTT, T., DUNBAR, H.M., MORRIS, S., ORR, S. and RUBIN, G.S., Patient and public preferences for health states associated with AMD. Optometry and vision science: official publication of the American Academy of Optometry, 2013;90(8):855-860.
BUTT, T., PATEL, P.J., TUFAIL, A. and RUBIN, G.S., Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity. Applied health economics and health policy, 2014;12(3):289-297.
CALDER, A.J. and YOUNG, A.W., Understanding the recognition of facial identity and facial expression. Nature reviews.Neuroscience, 2005;6(8):641-651.
CALVO, P., FERRERAS, A., AL ADEL, F., WANG, Y. and BRENT, M.H., Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. The British journal of ophthalmology, 2015;99(6):723-726.
71
CAMPBELL, R.J., GILL, S.S., BRONSKILL, S.E., PATERSON, J.M., WHITEHEAD, M. and BELL, C.M., Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors:
nested case-control study. BMJ (Clinical research ed.), 2012;345:e4203.
CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH [internet], Long-Term Use of Ranibizumab for the Treatment of Age-Related Macular Degeneration: A Review of the Clinical and Cost-Effectiveness and Guidelines. Cited 13 January 2016. Available from:
http://www.cadth.ca/media/pdf/htis/nov-2014/RC0533%20Lucentis%20for%20AMD%20final.pdf. 2014;.
CASTILLO, M.M., MOWATT, G., ELDERS, A., LOIS, N., FRASER, C., HERNANDEZ, R., AMOAKU, W., BURR, J.M., LOTERY, A., RAMSAY, C.R. and AZUARA-BLANCO, A., Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology, 2015;122(2):399-406.
CASTILLO, M.M., MOWATT, G., LOIS, N., ELDERS, A., FRASER, C., AMOAKU, W., BURR, J.M., LOTERY, A.J., RAMSAY, C.R. and AZUARA-BLANCO, A., Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review. Eye (London, England), 2014;28(12):1399-1406.
CATT RESEARCH GROUP, MARTIN, D.F., MAGUIRE, M.G., YING, G.S., GRUNWALD, J.E., FINE, S.L. and JAFFE, G.J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine, 2011;364(20):1897-1908.
CHAKRAVARTHY, U., GOLDENBERG, D., YOUNG, G., HAVILIO, M., RAFAELI, O., BENYAMINI, G. and LOEWENSTEIN, A., Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016;123(8):1731-6.
CHAKRAVARTHY, U., HARDING, S.P., ROGERS, C.A., DOWNES, S.M., LOTERY, A.J., CULLIFORD, L.A., REEVES, B.C. and IVAN STUDY INVESTIGATORS, Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet, 2013;382(9900):1258-1267.
CHANG, A.A., LI, H., BROADHEAD, G.K., HONG, T., SCHLUB, T.E., WIJEYAKUMAR, W.
and ZHU, M., Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology, 2014;121(1):188-192.
CHEN, G., LI, W., TZEKOV, R., JIANG, F., MAO, S. and TONG, Y., Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Retina (Philadelphia, Pa.), 2015;35(2):187-193.
CHIAPPA, K. and HILL, R., Pattern-Shift Visual Evoked Potentials: Interpretation. In: K.
CHIAPPA (Eds.), Evoked Potentials in Clinical Medicine. Third Edition edn. Philadelphia, United States of America. Lippincott - Raven Publishers. 1997;95-146.
72
CHIN-YEE, D., ECK, T., FOWLER, S., HARDI, A. and APTE, R.S., A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. The British journal of ophthalmology, 2015; doi:
10.1136/bjophthalmol-2015-306987.
CHO, H., SHAH, C.P., WEBER, M. and HEIER, J.S., Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. The British journal of ophthalmology, 2013;97(8):1032-1035.
CHOU, R., DANA, T., BOUGATSOS, C., GRUSING, S. and BLAZINA, I., Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Jama, 2016;315(9):915-933.
COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS (CATT) RESEARCH GROUP, MAGUIRE, M.G., MARTIN, D.F., YING, G.S., JAFFE, G.J., DANIEL, E., GRUNWALD, J.E., TOTH, C.A., FERRIS, F.L.,3rd and FINE, S.L., Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016;123(8):1751-61.
COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS (CATT) RESEARCH GROUP, MARTIN, D.F., MAGUIRE, M.G., FINE, S.L., YING, G.S., JAFFE, G.J., GRUNWALD, J.E., TOTH, C., REDFORD, M. and FERRIS, F.L.,3rd, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Ophthalmology, 2012;119(7):1388-1398.
CREEL, D.J. [internet], Visually Evoked Potentials. In H. KOLB, E. FERNANDEZ and R.
NELSON (Eds), Webvision: The Organization of the Retina and Visual System. Salt Lake City (UT).
1995. Cited 18 Februray 2016. Available from:
http://webvision.med.utah.edu/book/electrophysiology/visually-evoked-potentials/
CRUESS, A., ZLATEVA, G., XU, X. and ROCHON, S., Burden of illness of neovascular age-related macular degeneration in Canada. Canadian journal of ophthalmology.Journal canadien d'ophtalmologie, 2007;42(6):836-843.
CRUESS, A.F., ZLATEVA, G., XU, X., SOUBRANE, G., PAULEIKHOFF, D., LOTERY, A., MONES, J., BUGGAGE, R., SCHAEFER, C., KNIGHT, T. and GOSS, T.F., Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
PharmacoEconomics, 2008;26(1):57-73.
DAKIN, H.A., WORDSWORTH, S., ROGERS, C.A., ABANGMA, G., RAFTERY, J., HARDING, S.P., LOTERY, A.J., DOWNES, S.M., CHAKRAVARTHY, U., REEVES, B.C. and IVAN STUDY INVESTIGATORS, Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ open, 2014;4(7):e005094-2014-005094.
73
DANIEL, E., TOTH, C.A., GRUNWALD, J.E., JAFFE, G.J., MARTIN, D.F., FINE, S.L., HUANG, J., YING, G.S., HAGSTROM, S.A., WINTER, K., MAGUIRE, M.G. and COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS RESEARCH GROUP, Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology, 2014;121(3):656-666.
DE JONG, P.T., Age-related macular degeneration. The New England journal of medicine, 2006;355(14):1474-1485.
DE MORAES, C.G., Anatomy of the visual pathways. Journal of glaucoma, 2013;22 Suppl 5:S2-7.
DEDANIA, V.S. and BAKRI, S.J., Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: What Is the Evidence? Retina (Philadelphia, Pa.), 2015;35(5):841-858.
DEKOWSKA, M., KUNIECKI, M. and JASKOWSKI, P., Facing facts: neuronal mechanisms of face perception. Acta Neurobiologiae Experimentalis, 2008;68(2):229-252.
DI RUSSO, F., MARTINEZ, A., SERENO, M.I., PITZALIS, S. and HILLYARD, S.A., Cortical sources of the early components of the visual evoked potential. Human brain mapping, 2002;15(2):95-111.
DIAZ, R.I., SIGLER, E.J., RAFIEETARY, M.R. and CALZADA, J.I., Ocular histoplasmosis syndrome. Survey of ophthalmology, 2015;60(4):279-295.
DILKS, D.D., BAKER, C.I., PELI, E. and KANWISHER, N., Reorganization of visual processing in macular degeneration is not specific to the "preferred retinal locus". The Journal of neuroscience:
the official journal of the Society for Neuroscience, 2009;29(9):2768-2773.
DILKS, D.D., JULIAN, J.B., PELI, E. and KANWISHER, N., Reorganization of visual processing in age-related macular degeneration depends on foveal loss. Optometry and vision science: official publication of the American Academy of Optometry, 2014;91(8):e199-206.
DO, D.V., GOWER, E.W., CASSARD, S.D., BOYER, D., BRESSLER, N.M., BRESSLER, S.B., HEIER, J.S., JEFFERYS, J.L., SINGERMAN, L.J. and SOLOMON, S.D., Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study.
Ophthalmology, 2012;119(4):771-778.
DOLAN, P. and KAHNEMAN, D., Interpretations of utility and their implications for the valuation of health. The Economic Journal, 2008;118:215-234.
DROLET, D.W., GREEN, L.S., GOLD, L. and JANJIC, N., Fit for the Eye: Aptamers in Ocular Disorders. Nucleic acid therapeutics, 2016;26(3):127-46.
DRUMMOND, M.F., SCULPHER, M.J., TORRANCE, G.W., O'BRIEN, B.J. and STODDART, G.L., Methods for the economic evaluation of health care programmes. Oxford medical publications. 3rd edn. Oxford, England. Oxford University Press. 2005.
74
ELSHOUT, M., VAN DER REIS, M.I., WEBERS, C.A. and SCHOUTEN, J.S., The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2014;252(12):1911-20.
EMMERSON-HANOVER, R., SHEARER, D.E., CREEL, D.J. and DUSTMAN, R.E., Pattern reversal evoked potentials: gender differences and age-related changes in amplitude and latency. Electroencephalography and clinical neurophysiology, 1994;92(2):93-101.
FAIRHALL, S.L. and ISHAI, A., Effective connectivity within the distributed cortical network for face perception. Cerebral cortex (New York, N.Y.: 1991), 2007;17(10):2400-2406.
FERRINGTON, D.A., SINHA, D. and KAARNIRANTA, K., Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration. Progress in retinal and eye research, 2016;51:69-89.
FERRIS, F.L.,3rd, FINE, S.L. and HYMAN, L., Age-related macular degeneration and blindness due to neovascular maculopathy. Archives of ophthalmology (Chicago, Ill.: 1960), 1984;102(11):1640-1642.
FERRIS, F.L.,3rd, WILKINSON, C.P., BIRD, A., CHAKRAVARTHY, U., CHEW, E., CSAKY, K., SADDA, S.R. and BECKMAN INITIATIVE FOR MACULAR RESEARCH CLASSIFICATION COMMITTEE, Clinical classification of age-related macular degeneration. Ophthalmology, 2013;120(4):844-851.
FINE, S.L., BERGER, J.W., MAGUIRE, M.G. and HO, A.C., Age-related macular degeneration.
The New England journal of medicine, 2000;342(7):483-492.
FOLGAR, F.A., JAFFE, G.J., YING, G.S., MAGUIRE, M.G., TOTH, C.A. and COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS RESEARCH GROUP, Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology, 2014;121(10):1956-1965.
FOLK, J.C., THOMPSON, H.S., HAN, D.P. and BROWN, C.K., Visual function abnormalities in central serous retinopathy. Archives of Ophthalmology, 1984;102(9):1299-1302.
FRANCE, T.D., Electrophysiologic testing and its specific application in unsedated children.
Transactions of the American Ophthalmological Society, 1984;82:383-446.
FREUND, K.B., KOROBELNIK, J.F., DEVENYI, R., FRAMME, C., GALIC, J., HERBERT, E., HOERAUF, H., LANZETTA, P., MICHELS, S., MITCHELL, P., MONES, J., REGILLO, C., TADAYONI, R., TALKS, J. and WOLF, S., TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina (Philadelphia, Pa.), 2015;35(8):1489-1506.
75
FRITSCHE, L.G., CHEN, W., SCHU, M., YASPAN, B.L., YU, Y., THORLEIFSSON, G., ZACK, D.J., ARAKAWA, S., CIPRIANI, V., RIPKE, S., IGO, R.P.,Jr, BUITENDIJK, G.H., SIM, X., WEEKS, D.E., GUYMER, R.H., MERRIAM, J.E., FRANCIS, P.J., HANNUM, G., AGARWAL, A., ARMBRECHT, A.M., AUDO, I., AUNG, T., BARILE, G.R., BENCHABOUNE, M., BIRD, A.C., BISHOP, P.N., BRANHAM, K.E., BROOKS, M., BRUCKER, A.J., CADE, W.H., CAIN, M.S., CAMPOCHIARO, P.A., CHAN, C.C., CHENG, C.Y., CHEW, E.Y., CHIN, K.A., CHOWERS, I., CLAYTON, D.G., COJOCARU, R., CONLEY, Y.P., CORNES, B.K., DALY, M.J., DHILLON, B., EDWARDS, A.O., EVANGELOU, E., FAGERNESS, J., FERREYRA, H.A., FRIEDMAN, J.S., GEIRSDOTTIR, A., GEORGE, R.J., GIEGER, C., GUPTA, N., HAGSTROM, S.A., HARDING, S.P., HARITOGLOU, C., HECKENLIVELY, J.R., HOLZ, F.G., HUGHES, G., IOANNIDIS, J.P., ISHIBASHI, T., JOSEPH, P., JUN, G., KAMATANI, Y., KATSANIS, N., N KEILHAUER, C., KHAN, J.C., KIM, I.K., KIYOHARA, Y., KLEIN, B.E., KLEIN, R., KOVACH, J.L., KOZAK, I., LEE, C.J., LEE, K.E., LICHTNER, P., LOTERY, A.J., MEITINGER, T., MITCHELL, P., MOHAND-SAID, S., MOORE, A.T., MORGAN, D.J., MORRISON, M.A., MYERS, C.E., NAJ, A.C., NAKAMURA, Y., OKADA, Y., ORLIN, A., ORTUBE, M.C., OTHMAN, M.I., PAPPAS, C., PARK, K.H., PAUER, G.J., PEACHEY, N.S., POCH, O., PRIYA, R.R., REYNOLDS, R., RICHARDSON, A.J., RIPP, R., RUDOLPH, G., RYU, E., SAHEL, J.A., SCHAUMBERG, D.A., SCHOLL, H.P., SCHWARTZ, S.G., SCOTT, W.K., SHAHID, H., SIGURDSSON, H., SILVESTRI, G., SIVAKUMARAN, T.A., SMITH, R.T., SOBRIN, L., SOUIED, E.H., STAMBOLIAN, D.E., STEFANSSON, H., STURGILL-SHORT, G.M., TAKAHASHI, A., TOSAKULWONG, N., TRUITT, B.J., TSIRONI, E.E., UITTERLINDEN, A.G., VAN DUIJN, C.M., VIJAYA, L., ABECASIS, G.R. and AMD GENE CONSORTIUM, Seven new loci associated with age-related macular degeneration. Nature genetics, 2013;45(4):433-9.
FRITSCHE, L.G., IGL, W., BAILEY, J.N., GRASSMANN, F., SENGUPTA, S., BRAGG-GRESHAM, J.L., BURDON, K.P., HEBBRING, S.J., WEN, C., GORSKI, M., KIM, I.K., CHO, D., ZACK, D., SOUIED, E., SCHOLL, H.P., BALA, E., LEE, K.E., HUNTER, D.J., SARDELL, R.J., MITCHELL, P., MERRIAM, J.E., CIPRIANI, V., HOFFMAN, J.D., SCHICK, T., LECHANTEUR, Y.T., GUYMER, R.H., JOHNSON, M.P., JIANG, Y., STANTON, C.M., BUITENDIJK, G.H., ZHAN, X., KWONG, A.M., BOLEDA, A., BROOKS, M., GIESER, L., RATNAPRIYA, R., BRANHAM, K.E., FOERSTER, J.R., HECKENLIVELY, J.R., OTHMAN, M.I., VOTE, B.J., LIANG, H.H., SOUZEAU, E., MCALLISTER, I.L., ISAACS, T., HALL, J., LAKE, S., MACKEY, D.A., CONSTABLE, I.J., CRAIG, J.E., KITCHNER, T.E., YANG, Z., SU, Z., LUO, H., CHEN, D., OUYANG, H., FLAGG, K., LIN, D., MAO, G., FERREYRA, H., STARK, K., VON STRACHWITZ, C.N., WOLF, A., BRANDL, C., RUDOLPH, G., OLDEN, M., MORRISON, M.A., MORGAN, D.J., SCHU, M., AHN, J., SILVESTRI, G., TSIRONI, E.E., PARK, K.H., FARRER, L.A., ORLIN, A., BRUCKER, A., LI, M., CURCIO, C.A., MOHAND-SAID, S., SAHEL, J.A., AUDO, I., BENCHABOUNE, M., CREE, A.J., RENNIE, C.A., GOVERDHAN, S.V., GRUNIN,
76
M., HAGBI-LEVI, S., CAMPOCHIARO, P., KATSANIS, N., HOLZ, F.G., BLOND, F., BLANCHE, H., DELEUZE, J.F., IGO, R.P.,Jr, TRUITT, B., PEACHEY, N.S., MEUER, S.M., MYERS, C.E., MOORE, E.L., KLEIN, R., HAUSER, M.A., POSTEL, E.A., COURTENAY, M.D., SCHWARTZ, S.G., KOVACH, J.L., SCOTT, W.K., LIEW, G., TAN, A.G., GOPINATH, B., MERRIAM, J.C., SMITH, R.T., KHAN, J.C., SHAHID, H., MOORE, A.T., MCGRATH, J.A., LAUX, R., BRANTLEY, M.A.,Jr, AGARWAL, A., ERSOY, L., CARAMOY, A., LANGMANN, T., SAKSENS, N.T., DE JONG, E.K., HOYNG, C.B., CAIN, M.S., RICHARDSON, A.J., MARTIN, T.M., BLANGERO, J., WEEKS, D.E., DHILLON, B., VAN DUIJN, C.M., DOHENY, K.F., ROMM, J., KLAVER, C.C., HAYWARD, C., GORIN, M.B., KLEIN, M.L., BAIRD, P.N., DEN HOLLANDER, A.I., FAUSER, S., YATES, J.R., ALLIKMETS, R., WANG, J.J., SCHAUMBERG, D.A., KLEIN, B.E., HAGSTROM, S.A., CHOWERS, I., LOTERY, A.J., LEVEILLARD, T., ZHANG, K., BRILLIANT, M.H., HEWITT, A.W., SWAROOP, A., CHEW, E.Y., PERICAK-VANCE, M.A., DEANGELIS, M., STAMBOLIAN, D., HAINES, J.L., IYENGAR, S.K., WEBER, B.H., ABECASIS, G.R. and HEID, I.M., A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature genetics, 2016;48(2):134-143.
GASS, J.D. and OYAKAWA, R.T., Idiopathic juxtafoveolar retinal telangiectasis. Archives of ophthalmology (Chicago, Ill.: 1960), 1982;100(5):769-780.
GEHRS, K.M., ANDERSON, D.H., JOHNSON, L.V. and HAGEMAN, G.S., Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Annals of Medicine, 2006;38(7):450-471.
GEMENETZI, M. and LOTERY, A.J., The role of epigenetics in age-related macular degeneration. Eye (London, England), 2014;28(12):1407-1417.
GONG, J., YU, S., GONG, Y., WANG, F. and SUN, X., The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography. Journal of ophthalmology, 2016;2016:7521478.
GONZALEZ, E.G., TARITA-NISTOR, L., MANDELCORN, E.D., MANDELCORN, M. and STEINBACH, M.J., Fixation control before and after treatment for neovascular age-related macular degeneration. Investigative ophthalmology & visual science, 2011;52(7):4208-4213.
GRAGOUDAS, E.S., ADAMIS, A.P., CUNNINGHAM, E.T.,Jr, FEINSOD, M., GUYER, D.R. and VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP, Pegaptanib for neovascular age-related macular degeneration. The New England journal of medicine, 2004;351(27):2805-2816.
GRUNWALD, J.E., DANIEL, E., HUANG, J., YING, G.S., MAGUIRE, M.G., TOTH, C.A., JAFFE, G.J., FINE, S.L., BLODI, B., KLEIN, M.L., MARTIN, A.A., HAGSTROM, S.A., MARTIN, D.F.
and CATT RESEARCH GROUP, Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology, 2014;121(1):150-161.
77
GRUNWALD, J.E., PISTILLI, M., YING, G.S., MAGUIRE, M.G., DANIEL, E., MARTIN, D.F.
and COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS RESEARCH GROUP, Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology, 2015;122(4):809-816.
HALFELD FURTADO DE MENDONCA, R., MAIA, O.O.,Jr and YUKIHIKO TAKAHASHI, W., Electrophysiologic findings in chloroquine maculopathy. Documenta ophthalmologica. Advances in ophthalmology, 2007;115(2):117-119.
HANNULA, D.E., SIMONS, D.J. and COHEN, N.J., Imaging implicit perception: promise and pitfalls. Nature reviews. Neuroscience, 2005;6(3):247-255.
HANSO, L., BACHMANN, T. and MURD, C., Tolerance of the ERP signatures of unfamiliar versus familiar face perception to spatial quantization of facial images. Psychology, 2010;(1):199-208.
HANUS, J., ZHAO, F. and WANG, S., Current therapeutic developments in atrophic age-related macular degeneration. The British journal of ophthalmology, 2016;100(1):122-127.
HASLER, P.W., BLOCH, S.B., VILLUMSEN, J., FUCHS, J., LUND-ANDERSEN, H. and LARSEN, M., Safety study of 38,503 intravitreal ranibizumab injections performed mainly by
HASLER, P.W., BLOCH, S.B., VILLUMSEN, J., FUCHS, J., LUND-ANDERSEN, H. and LARSEN, M., Safety study of 38,503 intravitreal ranibizumab injections performed mainly by